The Retina Case Forum Webinar Series is an interactive web-based virtual meeting place for healthcare practitioners to review current concepts within retina. Each live webinar allows for peer-to-peer presentation with the creation of a comprehensive differential diagnosis, the interpretation of the results of diagnostic tests, and an exploration of the potential therapeutic options by identifying the advantages and drawbacks of each approach. Pre and post testing will allow for meaningful recognition of educational goals. The discussions will be of interest to retina specialists, comprehensive ophthalmologists, residents and fellows in training, and allied health professionals.

Exudative AMD Case Presentations

  • Update on the Comparative Effectiveness Trials for AMD

    Sumit Sharma, MD
  • Future Pathways for the Treatment of Exudative AMD

    David S. Boyer, MD
  • Exudative AMD Q&A Session

    Sumit Sharma, MD and David S. Boyer, MD
Launch Date

May 24, 2016

Expiration Date

May 24, 2017

Estimated Time to Complete

1 Hour

Hardware/Software Needed to Participate

High speed internet access

Target Audience

This activity is designed to meet the educational need of retina specialists, comprehensive ophthalmologists, residents and fellows in training , and allied healthcare professionals involved in the care of patients with retinal diseases such as diabetic retinopathy.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Summarize important findings from comparative effectiveness studies in exudative age related macular degeneration
  • Explore the potential methods for treating exudative age related macular degeneration
Method of Participation

In order to receive credit, participants should watch the entire video. Statements of credit will be awarded upon successful completion of the post test and online evaluation/claim credit form. If you have questions about this CME activity, please contact AKH Inc. at jgoldman@akhcme.com.

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

David S. Boyer, MD

  • Consultant: Alcon, a Novartis company; Allegro Ophthalmics, LLC; Allergan; Bausch & Lomb Incorporated; Genentech, Inc.; Neurotech USA; Ophthotech Corporation; Regeneron Pharmaceuticals, Inc.
  • Speaker Bureau: Alcon, a Novartis company; Allergan
  • Stock: Allegro Ophthalmics, LLC; Neurotech USA; Ohr Pharmaceutical, Inc.; Ophthotech Corporation

Sumit Sharma, MD

  • Nothing to Disclose
Planner Disclosures

Dorothy Caputo, MA, BSN, RN- CE Director of Accreditations

  • Nothing to Disclose

MCME Global Staff and Planners

  • Nothing to Disclose

AKH Staff and Planners

  • Nothing to Disclose
Commercial Support

This activity is supported by and educational grant from: Alcon, Inc.; Alimera Sciences; Allergan; Carl Zeiss; Optos; Regeneron Pharmaceuticals, Inc.; Santen Pharmaceutical

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use of Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc.

Advancing Knowledge in Healthcare    mcme-logo

This activity is supported by educational grants from:

Alcon
Alimera Sciences
Allergan
Optos
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical
Zeiss

X

PRE-QUESTIONS

Please answer the following pre-questions before moving on to the webinar presentation.

First Name*
Last Name*
Email*

The CATT study found bevacizumab to be _______ compared to ranibizumab

*
Superior
Inferior
Non-inferior

What percentage of eyes were 20/40 or better at 5 years in the CATT study?

*
30%
40%
50%
60%
70%

In a new patient who you diagnosed with wet-AMD receiving anti-VEGF therapy every four weeks for 3 months that has not responded your options include all the following but

*
Change anti-VEGF
Use dexamethasone intravitreal implant
Do ICG angiography to look for polypoidal disease or masquarade syndromes

Conditions that masquerade as Wet AMD include all of the following except:

*
Central serous
Pattern dystrophy
Polypoidal choroidal disease
Basal laminar drusen

In a new patient who you diagnosed with wet-AMD receiving anti-VEGF therapy every four weeks for 3 months that has not responded your options include all the following but

*
Change anti-VEGF
Have patient return in 2 weeks to see if there is a response
Dexamethasone intravitreal implant
Do ICG angiography to look for polypoidal disease or masquarade syndromes